10-K/A: Merit Medical Systems Files Amended 10-K to Correct Stock Performance Data

Merit Medical Systems has filed an amendment to its annual report to correct the five-year cumulative total return information for NASDAQ Stocks within its original filing.

Summary

• Merit Medical Systems filed an amendment (Form 10-K/A) to its original Annual Report on Form 10-K, which was initially filed on February 25, 2025.
• The amendment specifically addresses and restates Part II, Item 5, concerning the market for the registrant's common equity, related stockholder matters, and issuer purchases of equity securities.
• The purpose of the amendment is to correct the five-year cumulative total return information for NASDAQ Stocks (SIC 3840-3849 U.S. Companies Surgical, Medical and Dental Instruments and Supplies) contained within Part II, Item 5 of the Initial Filing.
• The total return information for Merit Medical's common stock and the NASDAQ US Benchmark TR Index presented in the Initial Filing remains unchanged.
• As of February 21, 2025, Merit Medical Systems had 58,834,568 shares of common stock outstanding.
• The company has never declared or paid cash dividends on its common stock and does not anticipate doing so in the foreseeable future.
• The filing includes a performance graph comparing Merit Medical's stock performance against the NASDAQ US Benchmark TR Index and NASDAQ Stocks (SIC 3840-3849 U.S. Companies) from December 31, 2019, to December 31, 2024.
• The amendment includes certifications from Fred P. Lampropoulos, President and CEO, and Raul Parra, CFO, regarding the accuracy of the information presented.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The document primarily corrects a data error, and the company's stock has outperformed relevant benchmarks. The lack of dividends is a negative, but it's a known factor.

Positives

• Merit Medical Systems' stock performance has outperformed the NASDAQ US Benchmark TR Index and the NASDAQ Stocks (SIC 3840-3849 U.S. Companies) index over the past five years (2019-2024).

Negatives

• The company has never declared or paid cash dividends on shares of its common stock.
• The company does not anticipate paying any dividends on shares of its common stock in the foreseeable future.

Risks

• Cash held by Merit Medical's subsidiary in China is subject to local laws and regulations that require government approval for the transfer of such funds to entities located outside of China, which may prevent such funds from being used to pay dividends.
• The company's Amended Fourth A&R Credit Agreement contains covenants prohibiting the declaration and distribution of a cash dividend at any time prior to the termination of the agreement.

Future Outlook

The company presently intends to retain any future earnings for use in its business and, therefore, does not anticipate paying any dividends on shares of its common stock in the foreseeable future.

Management Comments

• Fred P. Lampropoulos, President and CEO, certified that the report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report.
• Raul Parra, CFO, certified that the report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report.

Industry Context

The amendment addresses the accuracy of performance data relative to the broader NASDAQ Stocks (SIC 3840-3849 U.S. Companies Surgical, Medical and Dental Instruments and Supplies) index, which is a key benchmark for investors evaluating companies in the medical device sector.

Comparison to Industry Standards

• The document compares Merit Medical's stock performance against the NASDAQ US Benchmark TR Index and NASDAQ Stocks (SIC 3840-3849 U.S. Companies).
• The NASDAQ Stocks (SIC 3840-3849 U.S. Companies) index includes companies like Stryker, Boston Scientific, and Medtronic, which are major players in the surgical, medical, and dental instruments and supplies industry.
• The performance graph shows that Merit Medical's stock has outperformed the NASDAQ Stocks (SIC 3840-3849 U.S. Companies) index over the five-year period from December 31, 2019, to December 31, 2024.

Stakeholder Impact

• Shareholders will benefit from the corrected stock performance data, providing a more accurate view of the company's performance relative to industry benchmarks.

Key Dates

Keywords

Merit Medical Systems, 10-K/A, Amendment, Stock Performance, NASDAQ, Dividends, Financial Report